Under the terms of the agreement, Taconic paid Exelixis approximately $20 million, subject to certain post-closing adjustments, in exchange for an 80.1% ownership position in Artemis. Exelixis has the option to sell its remaining interest to Taconic, and Taconic also has an option to purchase Exelixis' remaining interest during certain times and under certain circumstances through 2015.
Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.
Artemis has developed a versatile technology platform in mouse genetics
and functional genomics. The company offers custom made genetically
engineered mouse models as in vivo genetic model systems for use at various
stages of the drug discovery process or in academic research. Models
produced by the ArteMice(TM) platform include knock out and "humanization"
platforms and platforms for generating inducible/reversible RNAi knock down
models and ASKA models for the inducible and reversible knock down of
kinases. These platforms are being continually expanded, most recently with
the addition of mouse models humanized for key drug metabolism enzyme
|SOURCE Exelixis, Inc.|
Copyright©2007 PR Newswire.
All rights reserved